Sözen S, Biri H, Sinik Z, Küpeli B, Alkibay T, Bozkirli I
Department of Urology, Gazi University School of Medicine, Ankara, Turkey.
Eur Urol. 1999 Sep;36(3):225-9. doi: 10.1159/000068002.
To assess sensitivity, specificity, accuracy, positive predictive value and negative predictive value of nuclear matrix protein 22 (NMP22) test, BTA stat test and cytology in the urine of patients with a spectrum of urologic conditions, including bladder cancer.
A total of 140 patients (40 with bladder cancer) provided a urine sample which was divided into appropriate aliquots for each of the tests cited above. The endoscopist, pathologist, cytologist and the person performing BTA stat test and NMP22 test were blinded as to the results of the other tests.
Receiver-operating characteristics curve interpretation determined that 12.0 U/ml was an optimal reference value for NMP22 to detect transitional cell carcinoma of the bladder in this patient group. Comparative results demonstrate a clear superiority of NMP22 and BTA stat tests in sensitivity in bladder cancer detection (p < 0.01), while cytology and NMP22 were better than BTA stat test in specificity (p < 0.05).
NMP22 and BTA stat test results represented significant improvement over urinary cytology for detection of transitional cell carcinoma. The sensitivities of NMP22 and BTA stat tests for detection of transitional cell carcinoma in this group of patients were as much as twice that of cytology. When the cutoff value of urinary NMP22 was set at 12.0 U/ml, NMP22 was more accurate than the other tests (p < 0.05).
评估核基质蛋白22(NMP22)检测、BTA stat检测及细胞学检查对包括膀胱癌在内的一系列泌尿系统疾病患者尿液的敏感性、特异性、准确性、阳性预测值和阴性预测值。
共有140例患者(40例膀胱癌患者)提供了尿液样本,将其分成适当的几份用于上述各项检测。内镜医师、病理学家、细胞学家以及进行BTA stat检测和NMP22检测的人员均对其他检测结果不知情。
通过受试者工作特征曲线分析确定,在该患者组中,NMP22检测膀胱癌的最佳参考值为12.0 U/ml。对比结果显示,NMP22检测和BTA stat检测在检测膀胱癌的敏感性方面具有明显优势(p < 0.01),而细胞学检查和NMP22检测在特异性方面优于BTA stat检测(p < 0.05)。
对于检测移行细胞癌,NMP22检测和BTA stat检测的结果相比尿液细胞学检查有显著改善。在该组患者中,NMP22检测和BTA stat检测检测移行细胞癌的敏感性高达细胞学检查的两倍。当尿液NMP22的临界值设定为12.0 U/ml时,NMP22检测比其他检测更准确(p < 0.05)。